View Older Stories View More Recent Stories

Sep 11, 2025 08:18AM RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'
Aug 25, 2025 06:05AM Raymond James Upgrades Dyne Therapeutics (DYN) to Strong Buy
Aug 6, 2025 11:20AM Dyne Therapeutics Inc. (DYN) gains following Avidity Biosciences Inc. (RNA) Takeover Rumors, Up 24%
Aug 4, 2025 08:31AM Stifel Reiterates Buy Rating on Dyne Therapeutics (DYN)
Jul 30, 2025 04:40PM Dyne Therapeutics (DYN) PT Lowered to $36 at Stifel
Jul 28, 2025 04:40PM Dynegy (DYN) Misses Q2 EPS by 3c
Jul 2, 2025 07:41AM Dyne Therapeutics (DYN) PT Lowered to $11.50 at Bernstein
Jun 30, 2025 04:05PM Dyne Therapeutics Inc. (DYN) Announces Proposed $200M Share Offering
Jun 30, 2025 04:02PM Dyne Therapeutics (DYN) Secures Up to $275 Million in Debt Financing from Hercules Capital
Jun 25, 2025 04:12PM Jones Trading Starts Dyne Therapeutics (DYN) at Buy
Jun 18, 2025 06:43AM H.C. Wainwright Reiterates Buy Rating on Dyne Therapeutics (DYN)
Jun 17, 2025 09:39AM Chardan Capital Markets Reiterates Buy Rating on Dyne Therapeutics (DYN) Following FDA Update
Jun 17, 2025 07:01AM Dyne Therapeutics (DYN) Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting
Jun 5, 2025 12:44PM FDA Cell and Gene Therapy Roundtable 'bullish for the space' - Stifel
Jun 2, 2025 08:52AM Oppenheimer Assumes Dyne Therapeutics (DYN) at Outperform (correction)
May 29, 2025 06:15AM Evercore ISI Starts Dyne Therapeutics (DYN) at Outperform
May 13, 2025 02:22PM Stifel Reiterates Buy Rating on Dyne Therapeutics (DYN), PT $66
May 12, 2025 06:57AM Dyne Therapeutics (DYN) PT Lowered to $38 at H.C. Wainwright
May 8, 2025 05:27PM Dynegy (DYN) Misses Q1 EPS by 20c
Apr 24, 2025 07:32AM Dyne Therapeutics Inc. (DYN) Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy
Apr 15, 2025 07:31AM Dyne Therapeutics Inc. (DYN) Announces Chief Business Officer and Chief Scientific Officer Appointments
Mar 26, 2025 05:58AM BMO Capital Reiterates Outperform Rating on Dyne Therapeutics (DYN)
Mar 20, 2025 04:25PM Dyne Therapeutics (DYN) PT Lowered to $17 at JPMorgan
Mar 20, 2025 04:11PM Dyne Therapeutics (DYN) Announces Appointment of Erick J. Lucera as Chief Financial Officer
Mar 17, 2025 09:39AM H.C. Wainwright Reiterates Buy Rating on Dyne Therapeutics (DYN)
Mar 17, 2025 08:08AM Piper Sandler Reiterates Overweight on Dyne Therapeutics (DYN) as 'DYNE-251 Continues to DELIVER'
Mar 17, 2025 07:56AM Stifel Reiterates Buy Rating on Dyne Therapeutics (DYN)
Mar 17, 2025 07:53AM Chardan Capital Markets Reiterates Buy Rating on Dyne Therapeutics (DYN)
Mar 11, 2025 04:11PM BMO Capital Starts Dyne Therapeutics (DYN) at Outperform
Mar 7, 2025 07:08AM Scotiabank Starts Dyne Therapeutics (DYN) at Sector Outperform
Feb 28, 2025 07:14AM Dyne Therapeutics (DYN) PT Lowered to $46 at H.C. Wainwright
Feb 28, 2025 06:47AM Dyne Therapeutics (DYN) PT Lowered to $48 at Piper Sandler
Jan 21, 2025 11:51AM Oppenheimer Reiterates Outperform Rating on Dyne Therapeutics (DYN), PT $60
Jan 21, 2025 07:30AM Dyne Therapeutics (DYN) Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
Jan 10, 2025 11:47AM Dyne Therapeutics Inc. (DYN) Reports New Clinical Data Showing Impact on Multiple Measures of Myotonic Dystrophy Type 1
Jan 2, 2025 12:51PM Biopharma 2025 Preview: 'Piper Sandler Sees Lots of Upside Opportunity'
Jan 2, 2025 07:17AM Oppenheimer Reiterates Outperform Rating on Dyne Therapeutics (DYN)
Dec 30, 2024 11:56AM Oppenheimer Reiterates Outperform Rating on Dyne Therapeutics (DYN)
Dec 12, 2024 04:08PM Baird Starts Dyne Therapeutics (DYN) at Outperform
Dec 2, 2024 12:37PM Piper Sandler highlights Dyne Therapeutics' (DYN) FORCE platform potential
Nov 26, 2024 05:13AM RBC Capital Starts Dyne Therapeutics (DYN) at Outperform
Nov 12, 2024 04:51PM Dynegy (DYN) Misses Q3 EPS by 25c
Oct 24, 2024 03:47AM JPMorgan Downgrades Dyne Therapeutics (DYN) to Neutral
Oct 9, 2024 07:30AM Dyne Therapeutics (DYN) Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases
Sep 23, 2024 07:14AM Piper Sandler Reiterates Overweight Rating on Dyne Therapeutics (DYN)
Sep 3, 2024 11:45AM Oppenheimer Reiterates Outperform Rating on Dyne Therapeutics (DYN)
Sep 3, 2024 07:19AM Dyne Therapeutics Inc. (DYN) Declines 20% Following New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251
Sep 3, 2024 06:32AM Dyne Therapeutics Inc. (DYN) Appoints Doug Kerr as CMO
Sep 3, 2024 06:30AM Dyne Therapeutics Inc. (DYN) Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251
Aug 13, 2024 09:05AM Dyne Therapeutics (DYN) PT Raised to $53 at Piper Sandler
View More Recent Stories View Older Stories